Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments (SOLO3)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02282020 |
|
Recruitment Status :
Active, not recruiting
First Posted : November 4, 2014
Last Update Posted : October 16, 2018
|
Sponsor:
AstraZeneca
Collaborators:
Myriad Genetic Laboratories, Inc.
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
AstraZeneca
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Comparison of olaparib vs. physician's choice of single agent standard of care non-platinum based chemotherapy in patients with germline Breast Cancer susceptibility gene (gBRCA) mutated ovarian cancer who have progressed at least 6 months after the last platinum based chemotherapy. Patient should have received at least 2 prior lines of platinum based chemotherapy. The aim of the study is to assess the efficacy and safety of olaparib tablets.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity | Drug: OLAPARIB Drug: Single agent chemotherapy | Phase 3 |
Expanded Access : An investigational treatment associated with this study has been approved for sale to the public. More info ...
This open label, randomised, controlled, multi-centre study will assess the efficacy and safety of single agent olaparib vs. standard of care, based on physician's choice of single agent chemotherapy ( i.e paclitaxel, or topotecan, or pegylated liposomal doxorubicin, or gemcitabine) in platinum sensitive or partially platinum sensitive relapsed ovarian cancer patients who carry germline deleterious or suspected deleterious BRCA mutation and who have received at least 2 prior lines of platinum based chemotherapy. Patients are eligible to undergo BRCA testing even if they have not yet had recurrence or progression of disease >6 months (>/=183 days) after completion of their last platinum therapy.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 266 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations. |
| Actual Study Start Date : | February 6, 2015 |
| Actual Primary Completion Date : | October 10, 2018 |
| Estimated Study Completion Date : | January 1, 2021 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Ovarian Cancer
Drug Information available for:
Olaparib
| Arm | Intervention/treatment |
|---|---|
|
Experimental: 1/OLAPARIB
olaparib 300mg oral tablets; twice daily
|
Drug: OLAPARIB
300 mg olaparib tablets taken orally twice daily. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria. |
|
Active Comparator: 2/CHEMOTHERAPY
Physician's choice single agent chemotherapy
|
Drug: Single agent chemotherapy
Treatment of relapsed disease with single agent chemotherapy based on physician's choice of weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria |
Primary Outcome Measures :
- Objective Response Rate (ORR) [ Time Frame: Primary endpoint will be assessed at the time of the primary analysis: a minimum of 6 months after LSI, whichever is sooner ]To determine the efficacy of olaparib vs. physician's choice single agent chemotherapy by assessment of Objective Response Rate (ORR) using blinded independent central review (BICR).
Secondary Outcome Measures :
- Overall Survival (OS) [ Time Frame: Time from randomization to death, at the time of the primary analysis (a minimum of 6 months after LSI, whichever is sooner), and at study completion, if different from the time of the primary analysis (estimated date - 01 Jan 2021). ]To determine the efficacy of olaparib vs. Physician's choice single agent chemotherapy by assessment of OS
- PFS 2 - time from randomisation to second progression [ Time Frame: Time from randomization to death, at the time of the primary analysis (a minimum of 6 months after LSI, whichever is sooner), and at study completion, if different from the time of the primary analysis (estimated date - 01 Jan 2021). ]To determine the efficacy of olaparib vs. Physician's choice single agent chemotherapy by assessment of time from randomisation up to second progression
- Time to earliest progression by RECIST 1.1 or Cancer Antigen (CA-125) or death [ Time Frame: Time from randomization to death, at the time of the primary analysis (a minimum of 6 months after LSI, whichever is sooner), and at study completion, if different from the time of the primary analysis (estimated date - 01 Jan 2021). ]To determine the efficacy of olaparib vs. Physician's choice single agent chemotherapy by assessment of time to earliest progression by CA-125 or death.
- Time to deterioration of Health-Related Quality of Life (HRQoL) as assessed by trial outcome index (TOI) and the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) [ Time Frame: Questionnaire completed at baseline, Day 29 and then every 8 weeks for 48 weeks. ]To determine the effects of olaparib vs. Physician's choice single agent chemotherapy by assessment of HRQoL as measured by TOI and FACT-O
- Time to first subsequent therapy or death (TFST). [ Time Frame: Time from randomization to death, at the time of the primary analysis (a minimum of 6 months after LSI, whichever is sooner), and at study completion, if different from the time of the primary analysis (estimated date - 01 Jan 2021). ]To determine the efficacy of olaparib vs. Physician's choice single agent chemotherapy by assessment of time from randomisation to first subsequent therapy or death (TFST).
- Time to second subsequent therapy or death (TSST). [ Time Frame: Time from randomization to death, at the time of the primary analysis (a minimum of 6 months after LSI, whichever is sooner), and at study completion, if different from the time of the primary analysis (estimated date - 01 Jan 2021). ]To determine the efficacy of olaparib vs. Physician's choice single agent chemotherapy by assessment of time from randomisation to second subsequent therapy or death (TSST).
- Time from randomisation to study treatment discontinuation or death (TDT). [ Time Frame: Time from randomization to death, at the time of the primary analysis (a minimum of 6 months after LSI, whichever is sooner), and at study completion, if different from the time of the primary analysis (estimated date - 01 Jan 2021). ]To determine the efficacy of olaparib vs. Physician's choice single agent chemotherapy by assessment of time from randomisation to study treatment discontinuation or death (TDT).
- Safety and tolerability of olaparib by assessment of the number of Adverse Events (AEs). [ Time Frame: Patients will be assessed until study treatment discontinuation, up until the end of the study estimated 01 Jan 2021. ]To assess the safety and tolerability of olaparib maintenance monotherapy
- Safety and tolerability of olaparib by review of laboratory parameters, ECG and vital signs [ Time Frame: Patients will be assessed until study treatment discontinuation, up until the end of the study estimated 01 Jan 2021. ]To assess the safety and tolerability of olaparib maintenance monotherapy
- Efficacy in patients following platinum based chemotherapy by assessment of time to earliest progression by RECIST or death [ Time Frame: Radiological assessments will be scheduled every 8 weeks (+/- 1 week) from randomisation for 48 weeks and every 12 weeks (+/- 1 week) thereafter until objective disease progression until study completion, estimated 01 Jan 2021 ]To determine the efficacy of olaparib vs. Physician's choice single agent chemotherapy by assessment of time to earliest progression by RECIST or death.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 130 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients must be ≥ 18 years of age
- Patients with histologically diagnosed relapsed high grade serous ovarian cancer (including primary peritoneal and/or fallopian tube cancer) or high grade endometrioid cancer. Patients are eligible to undergo BRCA testing even if they have not yet had recurrence or progression of disease >6 months (>/=183 days) after completion of their last platinum therapy.
- Documented germline mutation in Breast Cancer susceptibility genes: BRCA1 and/or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)
- At least one lesion that can be accurately assessed at baseline by CT/MRI and is suitable for repeated assessment.
- Patients must have received at least 2 prior platinum based lines of chemotherapy - Patients must be partially platinum sensitive or platinum sensitive
- Patients must be suitable to start treatment with single agent chemotherapy based on physician's choice
- Patients must have normal organ and bone marrow function measured within 28 days of randomisation,
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Patients must have a life expectancy ≥ 16 weeks
- Formalin fixed, paraffin embedded tumour sample from the primary or recurrent cancer must be available for central testing.
Exclusion Criteria:
- BRCA 1 and/or BRCA2 mutations that are considered to be non detrimental
- Exposure to any investigational product within 30 days or 5 half lives (whichever is longer) prior to randomisation
- Any previous treatment with a Polyadenosine 5'diphosphoribose polymerisation (PARP) inhibitor, including olaparib.
- Patients who have platinum resistant or refractory disease
- Patients receiving any systemic chemotherapy within 3 weeks prior to first dose of study treatment
- Previous single agent exposure to the selected chemotherapy regimen for randomisation. - Prior malignancy in the last 5 years, unless curatively treated and recurrence free (few exceptions apply).
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02282020
Show 79 Study Locations
Sponsors and Collaborators
AstraZeneca
Myriad Genetic Laboratories, Inc.
Merck Sharp & Dohme Corp.
Investigators
| Principal Investigator: | Richard T Penson, Associate Prof. of Medicine | Harvard Medical School |
Additional Information:
| Responsible Party: | AstraZeneca |
| ClinicalTrials.gov Identifier: | NCT02282020 History of Changes |
| Other Study ID Numbers: |
D0816C00010 |
| First Posted: | November 4, 2014 Key Record Dates |
| Last Update Posted: | October 16, 2018 |
| Last Verified: | October 2018 |
Keywords provided by AstraZeneca:
|
BRCA, ovarian, platinum, chemotherapy, |
Additional relevant MeSH terms:
|
Ovarian Neoplasms Neoplasms, Glandular and Epithelial Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Ovarian Diseases Adnexal Diseases Genital Diseases, Female Genital Neoplasms, Female |
Urogenital Neoplasms Endocrine System Diseases Gonadal Disorders Neoplasms by Histologic Type Olaparib Poly(ADP-ribose) Polymerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |